$REPL

Cantor Fitzgerald maintained an Overweight rating on Replimune Group (REPL), citing the launch of Tudriqev for melanoma. The stock has risen 176% in a year but may be overvalued, with cash burn concerns. Analysts' price targets range up to $24. Replimune's earnings report is due August 21, with potential 5.6% stock movement. Wedbush and Leerink also upgraded the stock, raising price targets to $19 and $17, respectively, following FDA approvals.

Replimune Group, Inc. (REPL) announced that TUDRIQEV™, a treatment for advanced melanoma, is now available in the U.S. The therapy, approved under accelerated approval, is indicated for adult patients who have progressed with PD-1-blocking antibody regimens. TUDRIQEV achieved a 24.2% objective response rate in clinical trials, with a median duration of 14.1 months. The company also launched a patient support program to assist with access and reimbursement.

Replimune's recent approval for Tudriqev, a melanoma immunotherapy, may signal a shift in early-stage cancer treatment. Experts highlight the potential of locally delivered therapies, with BMO Capital Markets estimating $1.3B annual sales for Tudriqev by 2035. Companies like Surge Therapeutics, Johnson & Johnson, and Ankyra Therapeutics are advancing similar treatments, aiming to improve efficacy and reduce toxicity.

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 15, 2026, Replimune Group, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals, each of which is described

Replimune (REPL) and uniQure (QURE) shares rose 7% and 5% respectively after FDA Commissioner Marty Makary resigned. Makary's departure followed clashes with the Trump administration over e-cigarette authorizations. The FDA previously rejected REPL's melanoma therapy and changed feedback on QURE's Huntington's disease treatment.

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

Replimune Group (REPL) faces securities class action lawsuits following the FDA's rejection of its RP1 Biologics License Application due to study design issues. The company will discuss its outlook at the Cantor Global Healthcare Conference. Analysts note increased regulatory and legal risks, with shares potentially trading above fair value.

Replimune (REPL) received FDA accelerated approval for its cancer therapy Tudriqev, despite staff concerns, after senior FDA leadership intervened. The Oncology Center of Excellence played a key role. Accelerated approval requires confirmatory trials. This marks a significant milestone for Replimune in the competitive oncology market.

Wedbush analyst Robert Driscoll raised Replimune Group's (REPL) price target to $9 from $6, maintaining a Neutral rating. The biotech company reported a fiscal year 2026 net loss of $313.9 million, with R&D and SG&A expenses increasing. The FDA accepted the resubmission of the BLA for RP1, setting a PDUFA goal date of August 2, 2026. The company's cash reserves decreased to $268.9 million as of March 31, 2026.